Compare Enveric Biosciences Inc (ENVB) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Lumen Technologies Inc — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Lumen Technologies Inc trades at $6.39 (market cap $6.56B). The key difference: Lumen Technologies Inc is far larger — about 1233.1× Enveric Biosciences Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | LUMN | |
|---|---|---|
Market Cap | $5.32M | $6.56B |
Sector | Health | Media |
52-Week High | $17.40 | $11.83 |
52-Week Low | $1.28 | $3.70 |
Enterprise Value | $408.82K | $18.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
LUMN trades at $6.37, down 1.24% for the day, with a bearish technical signal from moving averages. The company reported a net loss of $1.74 billion in 2025 despite beating EPS expectations in two of the last three quarters. Recent news highlights strategic acquisitions like Alkira to bolster its AI networking platform, while cash flow trends show operational strength but negative net cash flow due to heavy investing activities.
The outlook remains challenging with high debt and consistent losses, but cost-cutting initiatives and a $13 billion backlog offer potential upside. Risks include sustained negative profitability and competitive pressures in telecom. Analyst consensus is cautious with a hold-heavy rating and $8.25 price target, suggesting limited near-term optimism amid restructuring efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
